Cell-Free Cannabinoid Manufacturing via Reverse β-Oxidation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing cannabinoids and their intermediates, such as olivetolic acid and cannabigerolic acid, face challenges due to low yields and toxicity issues in chemical synthesis and microbial production, particularly limited by the supply of hexanoyl-CoA and toxicity of pathway intermediates.
Innovation Solution
A cell-free bio-manufacturing platform utilizing an optimized reverse β-oxidation pathway and biosynthetic enzymes from Cannabis sativa to produce hexanoyl-CoA, combined with a GPP-producing in vitro platform and engineered prenyltransferase NphB7, enabling the synthesis of cannabinoids and derivatives from simple carbon feedstocks like glucose.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chemical synthesis is used to produce cannabinoids, then product purity can be achieved, but yield is low and the process is complex
Solution Approach 1:
The patent replaces chemical synthesis methods with a cell-free biosynthetic system using purified enzymes from Cannabis sativa. This biological system catalyzes the conversion of fatty acid precursors to cannabinoids, achieving high yields (50 mg/L olivetolic acid) while maintaining product purity through enzymatic specificity, thus resolving the contradiction between yield and purity.
2Productivity
If cannabinoids are produced in microorganisms, then production can be scaled, but yield is limited by hexanoyl-CoA supply and intermediate toxicity
Solution Approach 1:
The patent extracts and purifies the biosynthetic enzyme pathway from Cannabis sativa plants, removing the problematic intracellular environment that causes intermediate toxicity and hexanoyl-CoA supply limitations. The cell-free system uses only the necessary enzymes (TKS, OAC, and others) in a controlled buffer system, eliminating the metabolic constraints that limited microbial production while maintaining scalability.
Solution Approach 2:
The patent introduces a cell-free enzymatic system as an intermediary between plant biosynthesis and microbial production. This system uses purified enzymes that convert exogenously supplied fatty acid precursors directly to cannabinoids, bypassing the need for endogenous hexanoyl-CoA synthesis and avoiding toxic intermediate accumulation, thus resolving the yield limitation while preserving scalability.
3Manufacturing precision
If isolated plant cannabinoids are used, then natural products are obtained, but isolation is challenging due to high similarity with other cannabinoids
Solution Approach 1:
The patent employs highly specific enzymes (TKS and OAC) that catalyze only the desired biosynthetic reactions with high regio- and stereospecificity. This enzymatic precision produces single isomers of cannabinoids without the mixture of similar compounds found in plant extraction, making product isolation trivial while ensuring natural product authenticity through faithful replication of plant biosynthesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The platform achieves significantly higher yields of olivetolic acid and cannabigerolic acid, with production rates 5-15 times higher than engineered microbial strains, demonstrating a scalable and efficient method for cannabinoid synthesis.
Implementation Method 1
an optimized reverse ß-oxidation pathway for the synthesis of hexanoyl-CoA
Implementation Method 2
biosynthetic enzymes from C. sativa yielded 50 mg/L olivetolic acid
Implementation Method 3
the engineered prenymltransferase NphB7 to produce the cannabinoid precursor CBGA
Data Source
AI summary
The invention relates to cell-free systems, methods, and kits for bio-manufacturing natural or chemical products from readily available feedstocks, such as glucose. The systems, methods, and kits allow for cell-free bio-manufacturing of desired products in cell-free conditions, and the rapid optimization of conditions for preparing the products in cell-free conditions. Disclosed herein are systems, methods, and kits for the cell-free production of fatty acids, cannabinoids, and their intermediates.